Furthermore, our finding of reduced mortality is in line with a meta-analysis of the cardiovascular outcome trials of SGLT2 inhibitors in patients with type 2 diabetes and established cardiovascular disease demonstrating a significant reduction in mortality.15 Here, SLC5A2 is linked to type 2 diabetes mellitus.